Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 5/20 | 0.49 |
| ▸ | ESR1 | P03372 | 4/20 | 0.49 |
| ▸ | MIF | P14174 | 1/20 | 0.46 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.42 |
| ▸ | ERN1 | O75460 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | BCR | P11274 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA3 | P07451 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9939715 | 0.82 | MIF (0.49) | ESR2ESR1MIFRXRAERN1 | |
| SCHEMBL9939026 | 0.80 | P2RY14 (0.60) | KDM4EMEN1KMT2ASRD5A2 | |
| SCHEMBL9939084 | 0.79 | MIF (0.49) | ESR2ESR1MIFERN1HSD17B10 | |
| SCHEMBL9939166 | 0.79 | MIF (0.49) | ESR2ESR1MIFERN1HSD17B10 | |
| SCHEMBL9939226 | 0.79 | ESR2 (0.50) | ESR2ESR1MIFRXRAERN1 | |
| SCHEMBL4138140 | 0.77 | ESR1 (0.49) | ESR2ESR1HSD17B10KDM4EMEN1 | |
| SCHEMBL8497041 | 0.77 | ESR1 (0.49) | ESR2ESR1MIFHSD17B10KDM4E | |
| SCHEMBL9939194 | 0.77 | ESR1 (0.56) | ESR2ESR1MIFRXRACYP2C8 | |
| SCHEMBL9939643 | 0.76 | ESR2 (0.49) | ESR2ESR1MIFERN1HSD17B10 | |
| SCHEMBL9939314 | 0.74 | ESR1 (0.73) | ESR2ESR1KDM4EABL1ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9249132-B2 | Substituted bicyclic aromatic compounds as S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2016-02-02 | — | — | US | claimed |
| EP-2651871-A1 | NOVEL SUBSTITUTED BICYCLIC AROMATIC COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 Pharmaceuticals, Inc. (US) | 2013-10-23 | — | — | EP | claimed |
| US-20130261122-A1 | Novel Substituted Bicyclic Aromatic Compounds as S-Nitrosoglutathione Reductase Inhibitors | N30 Pharmaceuticls, Inc. (US) | 2013-10-03 | — | — | US | claimed |
| CN-103328430-A | Novel substituted bicyclic aromatic compounds as s-nitrosoglutathione reductase inhibitors | N30 PHARMACEUTICALS LLC | 2013-09-25 | — | — | CN | claimed |
| WO-2012083171-A1 | NOVEL SUBSTITUTED BICYCLIC AROMATIC COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 PHARMACEUTICALS, LLC (US) | 2012-06-21 | — | — | WO | claimed |
| US-20160108011-A1 | Novel Substituted Bicyclic Aromatic Compounds as S-Nitrosoglutathione Reductase Inhibitors | N30 PHARMACEUTICALS, LLC | 2016-04-21 | — | — | US | disclosed |
| US-20160108011-A1 | Novel Substituted Bicyclic Aromatic Compounds as S-Nitrosoglutathione Reductase Inhibitors | N30 PHARMACEUTICALS, LLC | 2016-04-21 | — | — | US | disclosed |
| US-20160108011-A1 | Novel Substituted Bicyclic Aromatic Compounds as S-Nitrosoglutathione Reductase Inhibitors | N30 PHARMACEUTICALS, LLC | 2016-04-21 | — | — | US | disclosed |
| US-9249132-B2 | Substituted bicyclic aromatic compounds as S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-9249132-B2 | Substituted bicyclic aromatic compounds as S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-9249132-B2 | Substituted bicyclic aromatic compounds as S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| EP-2651871-A1 | NOVEL SUBSTITUTED BICYCLIC AROMATIC COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 Pharmaceuticals, Inc. (US) | 2013-10-23 | — | — | EP | disclosed |
| US-20130261122-A1 | Novel Substituted Bicyclic Aromatic Compounds as S-Nitrosoglutathione Reductase Inhibitors | N30 Pharmaceuticls, Inc. (US) | 2013-10-03 | — | — | US | disclosed |
| US-20130261122-A1 | Novel Substituted Bicyclic Aromatic Compounds as S-Nitrosoglutathione Reductase Inhibitors | N30 Pharmaceuticls, Inc. (US) | 2013-10-03 | — | — | US | disclosed |
| US-20130261122-A1 | Novel Substituted Bicyclic Aromatic Compounds as S-Nitrosoglutathione Reductase Inhibitors | N30 Pharmaceuticls, Inc. (US) | 2013-10-03 | — | — | US | disclosed |
| CN-103328430-A | Novel substituted bicyclic aromatic compounds as s-nitrosoglutathione reductase inhibitors | N30 PHARMACEUTICALS LLC | 2013-09-25 | — | — | CN | disclosed |
| WO-2012170371-A1 | COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 PHARMACEUTICALS, LLC (US) | 2012-12-13 | — | — | WO | disclosed |
| WO-2012083171-A1 | NOVEL SUBSTITUTED BICYCLIC AROMATIC COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 PHARMACEUTICALS, LLC (US) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012083171-A1 | NOVEL SUBSTITUTED BICYCLIC AROMATIC COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 PHARMACEUTICALS, LLC (US) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108011-A1 | Novel Substituted Bicyclic Aromatic Compounds as S-Nitrosoglutathione Reductase Inhibitors | GSR, CBR1, POR | ESR2 599/4885ESR1 908/4885MIF 4722/4885 |
| US-20130261122-A1 | Novel Substituted Bicyclic Aromatic Compounds as S-Nitrosoglutathione Reductase Inhibitors | GSR, CBR1, POR | ESR2 599/4885ESR1 908/4885MIF 4722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.